PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $16.43 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $25.81, a 22.21% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $21.12, a 41.91% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $36.36, a 1.06% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $35.98, a 27.87% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $28.69, a 21.27% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $36.44, a 17.71% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $44.28, a 75.71% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $25.20, a 7.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.43 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $25.81 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $28.69 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $29.02 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $29.37 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $21.12 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $36.44 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $36.14 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $34.88 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $36.36 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $44.28 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $43.04 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $36.22 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $35.98 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $25.20 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $26.53 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $50.39 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $49.88 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $23.48 10-K · filed 2022-02-25 | |||
| 2021-09-30 | $23.62 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $24.48 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $30.60 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $14.65 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $13.18 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $11.44 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $11.44 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $22.13 10-K · filed 2020-03-03 | |||
| 2019-09-30 | $34.54 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $34.43 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $39.28 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $43.42 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $47.51 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $49.80 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |